LENTIVIRAL VECTOR FOR GENE TRANSFER TO HEMATOPOIETIC STEM CELLS

用于基因转移至造血干细胞的慢病毒载体

• 批准号: 7715576
• 负责人: Donald B Kohn
• 金额: $ 10.84万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715576
• 关键词: Autologous; Behavior Therapy; Bone Marrow Transplantation; Busulfan; Computer Retrieval of Information on Scientific Projects Database; Funding; Gene Transfer; Grant; Hematopoietic stem cells; Human; Institution; Lentivirus Vector; Research; Research Personnel; Resources; Source; Stem cells; Transplantation; United States National Institutes of Health; conditioning; cytotoxic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: These studies focus on conditioning therapy (busulfan) for transplant of autologous transduced hematopoietic stem cells. Busulfan produces a specific loss of early stem cells and has been used as a stem cell cytotoxic conditioning agent prior to bone marrow transplantation in humans.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目的：这些研究重点是自体转导造血干细胞移植的预处理疗法（白消安）。白消安会造成早期干细胞的特定损失，并已在人体骨髓移植前用作干细胞的细胞毒性调节剂。